Share
Corleen Roche
Iovance Biotherapeutics, Inc., a commercial biotechnology company dedicated to innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has appointed Corleen Roche as Chief Financial Officer (CFO).
Bringing over 30 years of experience in the biotech and life sciences sector, Ms. Roche has held senior financial leadership roles in several publicly traded companies. Most recently, she served as CFO of CG Oncology, a late-stage clinical biopharmaceutical firm. Her previous leadership positions include CFO of Immunome, U.S. CFO at Biogen, North America CFO at CSL Behring, and various CFO roles within Sandoz, Wyeth, and Pfizer.
Throughout her career, Ms. Roche has spearheaded financial strategies to support major commercial launches, including ZARXIO®, the first U.S.-approved biosimilar; GLATOPA™, the world’s first complex generic for multiple sclerosis; and PREVNAR 13®, a pneumococcal conjugate vaccine. She holds a B.A. in Accountancy from Villanova University.
